Pyrimidine scaffold dual-target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)
Song M. Elkamhawy A. Noh W. Abdelazem A.Z. Park Y. Sivaraman A. Bertleuova A. Atef D. Lee K.
January 2025John Wiley and Sons Inc
Archiv der Pharmazie
2025#358Issue 1
Cancer, the second leading cause of death globally, causes a significant threat to life. Despite advancements in the treatment of cancer, persistent challenges include severe side effects and the emergence of acquired drug resistance. Additionally, many traditional chemotherapy drugs show restricted efficacy and high toxicity, primarily attributed to their lack of selectivity. Thus, the development of drugs targeting protein kinases has emerged as a noteworthy priority for addressing human cancers. Medicinal chemists have shown considerable interest in the development of dual drug candidates as a strategy to create medicines that are safer, more efficient, and cost-effective. Furthermore, the Food and Drug Administration (FDA) has approved several dual-target drugs for anticancer treatment, emphasizing their lower risks of drug interactions and improved pharmacokinetics and safety profiles. This review focuses on the synthetic efforts, design strategies, and structure–activity relationship of the pyrimidine scaffold-based dual kinase inhibitors developed with anticancer potential within the recent 6 years (2018‒2023). Collectively, these strategies are expected to offer fresh perspectives on the future directions of pyrimidine-based dual-target kinase drug design, potentially advancing cancer therapeutics.
anticancer , dual-target inhibition , kinase inhibitors , pyrimidine , targeted cancer therapy
Text of the article Перейти на текст статьи
BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul, South Korea
Department of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan
Biotechnology & Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, suef, Beni, Egypt
Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
BK21 FOUR Team and Integrated Research Institute for Drug Development
Department of Chemistry
Biotechnology & Life Sciences Department
Faculty of Pharmacy
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026